$0.78-0.02|(-2.66%)
52W H: 1.38552W L: 0.5Beta: 0.97

About Elutia Inc

  • Industry: Biotechnology
  • Exchange: NASDAQ NMS - GLOBAL MARKET
  • Country: US
  • Website: https://elutia.com/

Frequently Asked Questions

What is the 52-week range for ELUT?

The 52-week high is $1.385 and the 52-week low is $0.5.

What is the P/E ratio for ELUT?

The Price to Earnings (P/E) ratio is 0.67.

What is the dividend yield for ELUT?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is 253.28%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is 426.93%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 1.07.

Analyst Recommendation Trends

Wall Street analyst consensus for ELUT over the last few months:

2026-09-01
Buy: 4
S.Buy: 2
Hold: 1
Sell: 0
2026-08-01
Buy: 4
S.Buy: 2
Hold: 1
Sell: 0
2026-07-01
Buy: 4
S.Buy: 2
Hold: 1
Sell: 0
2026-06-01
Buy: 4
S.Buy: 2
Hold: 1
Sell: 0

Latest ELUT News

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers NewGenIvf Group (NASDAQ:NIVF) stock moved upwards by 56.7% to $0.16 during Friday's pre-market session. Stablecoin Development (AMEX:SDEV) stock rose 30.86% to $4.79. The company's market cap stands at

Benzinga10/2/2026

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix t

Yahoo10/1/2026

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions (NASDAQ:INBS)

Benzinga10/1/2026

Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029

Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of

Benzinga10/1/2026

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on Septe

Yahoo9/10/2026

Related Stocks (Peers)

Companies operating in similar sectors to ELUT:

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-09-10Williams Michelle LeRoux-12,500--
2026-09-10Williams Michelle LeRoux-4,269$0.8$3,415
2026-09-10Williams Michelle LeRoux+12,500--
2026-09-10Mills C Randal-27,083--
2026-09-10Mills C Randal-9,718$0.8$7,774
2026-09-10Mills C Randal+27,083--
2026-09-10Ferguson Matthew-12,500--
2026-09-10Ferguson Matthew-4,486$0.8$3,589
2026-09-10Ferguson Matthew+12,500--
2026-06-21Mills C Randal-22,473--
2026-06-21Mills C Randal-8,064$1.06$8,548
2026-06-21Mills C Randal+22,473--
2026-06-11Colpman David+106,393--
2026-06-11Makes Brigid+106,393--
2026-06-11NEELS GUIDO J+106,393--
2026-06-11RAKIN KEVIN+159,590--
2026-06-10Williams Michelle LeRoux-12,500--
2026-06-10Williams Michelle LeRoux-4,269$1.04$4,440
2026-06-10Williams Michelle LeRoux+12,500--
2026-06-10Mills C Randal-27,083--
2026-06-10Mills C Randal-9,718$1.04$10,107
2026-06-10Mills C Randal+27,083--
2026-06-10Ferguson Matthew-12,500--
2026-06-10Ferguson Matthew-4,485$1.04$4,664
2026-06-10Ferguson Matthew+12,500--
2026-06-01RAKIN KEVIN-50,000--
2026-06-01RAKIN KEVIN-70,000--
2026-03-10Williams Michelle LeRoux-12,500--
2026-03-10Williams Michelle LeRoux-4,613$1.09$5,028
2026-03-10Williams Michelle LeRoux+12,500--
2026-03-10Mills C Randal-27,084--
2026-03-10Mills C Randal-11,100$1.09$12,099
2026-03-10Mills C Randal+27,084--
2026-03-10Ferguson Matthew-12,500--
2026-03-10Ferguson Matthew-5,123$1.09$5,584
2026-03-10Ferguson Matthew+12,500--
2026-01-30NEELS GUIDO J+20,000$1.04$20,800
2026-01-30RAKIN KEVIN+70,000$1.06$74,200
2026-01-29NEELS GUIDO J+15,000$1.06$15,900
2026-01-28NEELS GUIDO J+15,000$1.06$15,900
2026-01-01Williams Michelle LeRoux+368,000--
2026-01-01Mills C Randal+726,000--
2026-01-01Ferguson Matthew+368,000--
2025-12-17RAKIN KEVIN+50,000$0.5199$25,995
2025-12-17Colpman David+12,500$0.51$6,375
2025-12-17Makes Brigid+25,000$0.52$13,000
2025-12-17Mills C Randal+3,000$0.51$1,530
2025-12-17Ferguson Matthew+60,000$0.53$31,800
2025-12-11RAKIN KEVIN-4,505,941--
2025-12-11RAKIN KEVIN-4,505,941--
2025-12-11RAKIN KEVIN-4,372,497--
2025-12-10NEELS GUIDO J-6,250--
2025-12-10NEELS GUIDO J+6,250--
2025-12-10Williams Michelle LeRoux-12,500--
2025-12-10Williams Michelle LeRoux-3,951$0.7$2,766
2025-12-10Williams Michelle LeRoux+12,500--
2025-12-10Mills C Randal-27,083--
2025-12-10Mills C Randal-9,664$0.7$6,765
2025-12-10Mills C Randal+27,083--
2025-12-10Ferguson Matthew-12,500--
2025-12-10Ferguson Matthew-4,461$0.7$3,123
2025-12-10Ferguson Matthew+12,500--
2025-12-02Ferguson Matthew+5,500$0.67$3,685
2025-12-01Ferguson Matthew+4,500$0.65$2,925
2025-12-01NEELS GUIDO J-6,250--
2025-12-01NEELS GUIDO J+6,250--
2025-11-24Mills C Randal+5,000$0.6$3,000
2025-11-17Colpman David+15,500$0.74$11,470
2025-11-13Mills C Randal+3,500$0.76$2,660
2025-11-13Mills C Randal+5,000$0.75$3,750
2025-11-13Mills C Randal+5,000$0.74$3,700
2025-10-09NEELS GUIDO J+171,916--